相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Jatta Saarenheimo et al.
FRONTIERS IN ONCOLOGY (2019)
Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology
Roshni Ann Mathai et al.
JOURNAL OF CLINICAL MEDICINE (2019)
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study
Yung-Hung Luo et al.
LANCET ONCOLOGY (2019)
LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2019)
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
Hongfu Cai et al.
CLINICAL THERAPEUTICS (2019)
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
Yen-Ting Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
Masayuki Takeda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers
Dong Xie et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2018)
Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience
Nadza Tokaca et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy
Bin Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 expression in lung adenocarcinoma harboring &ITEGFR&IT mutations or &ITALK&IT rearrangements
Yasuto Yoneshima et al.
LUNG CANCER (2018)
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
Sanjay Popat
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Gregory P. Kalemkerian et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
Maximilian J. Hochmair et al.
FUTURE ONCOLOGY (2018)
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
Vera Hirsh
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
E. Iwama et al.
ANNALS OF ONCOLOGY (2017)
Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer
Jinfeng He et al.
FUTURE ONCOLOGY (2017)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
Keita Masuzawa et al.
ONCOTARGET (2017)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
S7681 Mutation Mutation in EGFR in Patients with Lung Cancer
Konstantinos Leventakos et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Trends in Subpopulations at High Risk for Lung Cancer
Ping Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015
Haidong Wang et al.
LANCET (2016)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
Natasha B. Leighl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Alexis B. Cortot et al.
EUROPEAN RESPIRATORY REVIEW (2014)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
Kadoaki Ohashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
